CD19 and diffuse large B-cell lymphoma: Loncastuximab tesirine, an anti‐CD19 conjugated ADC, received accelerated FDA approval for treating R/R DLBCL after two or more lines of therapy, based on phase II multicenter LOTIS‐2 trial results.34, 35